Ajai Chari, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address600 16th Street, #A456
San Francisco CA 94158
Phone415-353-2421
PronounsHe/Him/His
ORCID ORCID Icon0000-0002-0405-7480 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Stanford Univeristy, Palo Alto, CABA, BS06/1994Psychology, Biology
    UCLA, Los AngelesMD06/1999Medicine
    NYPH Columbia Presbyterian Medical Center, New York06/2002Internal Medicine Residency
    UCSF, San Francisco06/2005Hematology/Oncology Fellowship

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma. Blood Adv. 2025 Jan 14; 9(1):176-179. Chen LY, Thibaud S, Bodnar S, Chari A, Richter J, Cho HJ, Sanchez LJ, Rodriguez C, Rossi AC, Richard S, Parekh S, Jagannath S. PMID: 39546749.
      View in: PubMed   Mentions:    Fields:    
    2. Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS. Blood. 2024 Dec 09. Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees PM, Sandhu I, Jenner MW, Smith D, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Vieyra D, Sha L, Li L, Rousseau E, Dennis RM, Carson R, Hofmeister CC. PMID: 39652826.
      View in: PubMed   Mentions:    Fields:    
    3. Multiple Myeloma Risk and Outcomes Are Associated with Pathogenic Germline Variants in DNA Repair Genes. Blood Cancer Discov. 2024 Nov 01; 5(6):428-441. Thibaud S, Subaran RL, Newman S, Lagana A, Melnekoff DT, Bodnar S, Ram M, Soens Z, Genthe W, Brander T, Mouhieddine TH, Van Oekelen O, Houldsworth J, Cho HJ, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez L, Chari A, Moshier E, Jagannath S, Parekh S, Onel K. PMID: 39283238; PMCID: PMC11528192.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    4. Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant. 2024 Oct 18. Avigan ZM, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, Milkovich G, Moshier E, Fu W, Chari A, Richter J. PMID: 39424960.
      View in: PubMed   Mentions:    Fields:    
    5. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024 09 12; 14(1):158. Devasia AJ, Chari A, Lancman G. PMID: 39266530; PMCID: PMC11393350.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Matching-adjusted indirect comparison of talquetamab vs selinexor-dexamethasone and vs belantamab mafodotin in patients with relapsed/refractory multiple myeloma. Curr Med Res Opin. 2024 Oct; 40(10):1769-1783. Reece D, Diels J, Van Sanden S, Pei L, Ammann E, Heuck C, Kane C, Londhe A, Peterson S, Chari A. PMID: 39226081.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    7. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024 Sep; 56(9):1878-1889. Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, Orloff G, Jakubowiak A, Niesvizky R, Liles D, Berdeja J, Levy M, Wolf J, Usmani SZ, MMRF CoMMpass Network, Christofferson AW, Nasser S, Aldrich JL, Legendre C, Benard B, Miller C, Turner B, Kurdoglu A, Washington M, Yellapantula V, Adkins JR, Cuyugan L, Boateng M, Helland A, Kyman S, McDonald J, Reiman R, Stephenson K, Tassone E, Blanski A, Livermore B, Kirchhoff M, Rohrer DC, D'Agostino M, Gamella M, Collison K, Stumph J, Kidd P, Donnelly A, Zaugg B, Toone M, McBride K, DeRome M, Rogers J, Craig D, Liang WS, Gutierrez NC, Jewell SD, Carpten J, Anderson KC, Cho HJ, Auclair D, Lonial S, Keats JJ. PMID: 39160255; PMCID: PMC11387199.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    8. Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. Bone Marrow Transplant. 2024 Oct; 59(10):1440-1448. Avigan ZM, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, Milkovich G, Moshier E, Fu W, Chari A, Richter J. PMID: 39085373.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    9. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 2024 Sep; 11(9):e693-e707. van de Donk NWCJ, Chari A, Mateos MV. PMID: 39033769.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    10. Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 07 08; 14(1):107. Chari A, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. PMID: 38977707; PMCID: PMC11231363.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    11. Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab. Clin Lymphoma Myeloma Leuk. 2024 Oct; 24(10):665-693.e14. Chari A, Krishnan A, Rasche L, Ye JC, Garfall A, Popat R, Lipe B, Qin X, Campagna M, Masterson T, Tomlinson C, Hilder B, Tolbert J, Renaud T, Smit MD, Gray K, Kane C, Heuck C, van de Donk NWCJ. PMID: 38871558.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    12. Salvage therapies including retreatment with BCMA-directed approaches after BCMA CAR-T relapses for multiple myeloma. Blood Adv. 2024 05 14; 8(9):2207-2216. Reyes KR, Liu YC, Huang CY, Banerjee R, Martin T, Wong SW, Wolf JL, Arora S, Shah N, Chari A, Chung A. PMID: 38429087; PMCID: PMC11061209.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    13. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024 05; 25(5):e205-e216. Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Gállego Pérez-Larraya J, Manier S, Nooka AK, Mateos MV, Einsele H, Minnema M, Cavo M, Derman BA, Puig N, Gay F, Ho PJ, Chng WJ, Kastritis E, Gahrton G, Weisel K, Nagarajan C, Schjesvold F, Mikhael J, Costa L, Raje NS, Zamagni E, Hájek R, Weinhold N, Yong K, Ye JC, Sidhana S, Merlini G, Martin T, Lin Y, Chari A, Popat R, Kaufman JL, International Myeloma Working Group. PMID: 38697166.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    14. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024 04 22; 14(1):69. Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM. PMID: 38649340; PMCID: PMC11035596.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 07; 99(7):1257-1268. Silbermann R, Laubach J, Kaufman JL, Sborov DW, Reeves B, Rodriguez C, Chari A, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Orlowski RZ, Shain KH, Cowan AJ, Gries KS, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. PMID: 38622840.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    16. Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma. J Immunother Cancer. 2024 Apr 12; 12(4). Coffey DG, Osman K, Aleman A, Bekri S, Kats S, Dhadwal A, Catamero D, Kim-Schulze S, Gnjatic S, Chari A, Parekh S, Jagannath S, Cho HJ. PMID: 38609316; PMCID: PMC11029259.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsCTClinical Trials
    17. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study. Br J Haematol. 2024 Jun; 204(6):2227-2232. Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes TM, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Lin TS, Voorhees PM, Usmani SZ, Richardson PG. PMID: 38504552.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024 Mar 06; 14(1):40. Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. PMID: 38448422; PMCID: PMC10918080.
      View in: PubMed   Mentions:    Fields:    
    19. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024 02 02; 14(1):24. Rodriguez-Otero P, van de Donk NWCJ, Pillarisetti K, Cornax I, Vishwamitra D, Gray K, Hilder B, Tolbert J, Renaud T, Masterson T, Heuck C, Kane C, Verona R, Moreau P, Bahlis N, Chari A. PMID: 38307865; PMCID: PMC10837198.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    20. Role of Consolidation and Maintenance. Hematol Oncol Clin North Am. 2024 04; 38(2):421-440. Kumar AD, Chari A. PMID: 38262780.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups. Blood Adv. 2024 01 09; 8(1):236-247. Shah UA, Moshier E, Derkach A, Huang Y, Mailankody S, Tan CR, Maclachlan K, Hultcrantz M, Korde N, Hassoun H, Thibaud S, Sanchez L, Rodriguez C, Richard S, Richter J, Rossi A, Cho HJ, Lesokhin A, Chari A, Usmani SZ, Jagannath S, Parekh S, Gallagher EJ. PMID: 37772981; PMCID: PMC10918423.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    22. Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):194-202. Martin TG, Moreau P, Usmani SZ, Garfall A, Mateos MV, San-Miguel JF, Oriol A, Nooka AK, Rosinol L, Chari A, Karlin L, Krishnan A, Bahlis N, Popat R, Besemer B, Martínez-López J, Delforge M, Trancucci D, Pei L, Kobos R, Fastenau J, Gries KS, van de Donk NWCJ. PMID: 38052709.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    23. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023 11 01; 4(6):440-451. Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, Cho HJ, Parekh SS, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez LJ, Thibaud S, Jagannath S, Chari A. PMID: 37769148; PMCID: PMC10618720.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    24. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. J Manag Care Spec Pharm. 2023 Nov; 29(11):1205-1218. Sanchez L, Chari A, Cheng M, Cherepanov D, DerSarkissian M, Huang F, Stull DM, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Ailawadhi S. PMID: 37776124; PMCID: PMC10776283.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    25. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837. Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. PMID: 37708911.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    26. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial. Cancer. 2023 12 01; 129(23):3746-3760. Nooka AK, Cohen AD, Lee HC, Badros A, Suvannasankha A, Callander N, Abdallah AO, Trudel S, Chari A, Libby EN, Chaudhry M, Hultcrantz M, Kortüm KM, Popat R, Sborov D, Hakim S, Lewis E, Gorsh B, Bhushan B, McKeown A, Gupta I, Opalinska J, Richardson PG, Lonial S. PMID: 37622738; PMCID: PMC11055177.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    27. Plain language summary of the MonumenTAL-1 study of talquetamab in people with relapsed or refractory multiple myeloma. Future Oncol. 2023 Sep; 19(27):1823-1840. Chari A, Askari E, Caers J, Costa LJ, Hilder BW, Krishnan A, Mateos MV, Minnema MC, Oriol A, Pillarisetti K, van de Donk NWCJ, Rodríguez-Otero P. PMID: 37492991.
      View in: PubMed   Mentions: 2     Fields:    
    28. Expert Consensus on the Incorporation of Anti-CD38 Monoclonal Antibody Therapy Into the Management of Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 11; 23(11):815-824. Lonial S, Bowser AD, Chari A, Costello C, Krishnan A, Usmani SZ. PMID: 37516547.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    29. Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma. J Comp Eff Res. 2023 06; 12(6):e220186. Krishnan A, Nooka AK, Chari A, Garfall AL, Martin TG, Nair S, Lin X, Qi K, Londhe A, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Usmani SZ. PMID: 37114426; PMCID: PMC10402759.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    30. Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma. Blood Adv. 2023 03 28; 7(6):1056-1064. Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. PMID: 36018226; PMCID: PMC10033902.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    31. Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS. Blood Cancer J. 2023 03 07; 13(1):33. Moreau P, Chari A, Oriol A, Martinez-Lopez J, Haenel M, Touzeau C, Ailawadhi S, Besemer B, de la Rubia Comos J, Encinas C, Mateos MV, Salwender H, Rodriguez-Otero P, Hulin C, Karlin L, Sureda Balari A, Bargay J, Benboubker L, Rosiñol L, Tarantolo S, Terebelo H, Yang S, Wang J, Nnane I, Qi M, Kosh M, Delioukina M, Goldschmidt H. PMID: 36882409; PMCID: PMC9989580.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):385-393. Mateos MV, Chari A, Usmani SZ, Goldschmidt H, Weisel K, Qi K, Londhe A, Nair S, Lin X, Pei L, Ammann E, Kobos R, Smit J, Parekh T, Marshall A, Slavcev M, Moreau P. PMID: 36967244.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    33. Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy. Blood. 2023 02 16; 141(7):756-765. Van Oekelen O, Nath K, Mouhieddine TH, Farzana T, Aleman A, Melnekoff DT, Ghodke-Puranik Y, Shah GL, Lesokhin A, Giralt S, Thibaud S, Rossi A, Rodriguez C, Sanchez L, Richter J, Richard S, Cho HJ, Chari A, Usmani SZ, Jagannath S, Shah UA, Mailankody S, Parekh S. PMID: 36327160; PMCID: PMC10082354.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    34. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May; 110(5):564-570. Derman BA, Chari A, Zonder J, Major A, Stefka AT, Jiang K, Karrison T, Jasielec J, Jakubowiak A. PMID: 36726221.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    35. Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study. Leuk Lymphoma. 2023 02; 64(2):468-472. Nahi H, Usmani SZ, Mateos MV, van de Donk NWCJ, Oriol A, Plesner T, Bandyopadhyay N, Hellemans P, Tromp B, Nnane I, Zemlickis D, Chari A, Moreau P. PMID: 36593729.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    36. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma. N Engl J Med. 2022 12 15; 387(24):2232-2244. Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk NWCJ, Rodríguez-Otero P, Askari E, Mateos MV, Costa LJ, Caers J, Verona R, Girgis S, Yang S, Goldsmith RB, Yao X, Pillarisetti K, Hilder BW, Russell J, Goldberg JD, Krishnan A. PMID: 36507686.
      View in: PubMed   Mentions: 165     Fields:    Translation:HumansCellsCTClinical Trials
    37. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2023 03; 23(3):e171-e181. Thompson MA, Boccadoro M, Leleu X, Vela-Ojeda J, van Rhee F, Weisel KC, Rifkin RM, Usmani SZ, Hájek R, Cook G, Abonour R, Armour M, Morgan KE, Yeh SP, Costello CL, Berdeja JG, Davies FE, Zonder JA, Lee HC, Omel J, Spencer A, Terpos E, Hungria VTM, Puig N, Fu C, Ferrari RH, Ren K, Stull DM, Chari A. PMID: 36641358.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    38. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials. Transplant Cell Ther. 2023 03; 29(3):174.e1-174.e10. Chhabra S, Callander N, Watts NL, Costa LJ, Thapa B, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Anderson LD, Bal S, Dhakal B, Nathwani N, Shah N, Medvedova E, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Schmidt T, Orlowski RZ, Shain KH, Cowan AJ, Dholaria B, Cornell RF, Jerkins JH, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG, Voorhees PM. PMID: 36494017.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    39. Trial designs and endpoints for immune therapies in multiple myeloma. Am J Hematol. 2023 03; 98 Suppl 2:S35-S45. Lancman G, Moshier E, Cho HJ, Parekh S, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez L, Jagannath S, Chari A. PMID: 36200130.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    40. Bridging advanced myeloma patients to subsequent treatments and clinical trials with classical chemotherapy and stem cell support. Bone Marrow Transplant. 2023 01; 58(1):80-86. Mouhieddine TH, Moshier E, Thibaud S, Puliafito B, Rattu M, Jakubowski R, Sanchez L, Rossi A, Rodriguez C, Richard S, Cho HJ, Parekh S, Chari A, Steinberg A, Richter J. PMID: 36261708.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Duration of frontline therapy and impact on clinical outcomes in newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant. Cancer Med. 2023 02; 12(3):3145-3159. Ailawadhi S, Ogbonnaya A, Murty S, Cherepanov D, Schroader BK, Romanus D, Farrelly E, Chari A. PMID: 36151787; PMCID: PMC9939178.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    42. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study. Br J Haematol. 2022 11; 199(3):355-365. Sborov DW, Baljevic M, Reeves B, Laubach J, Efebera YA, Rodriguez C, Costa LJ, Chari A, Silbermann R, Holstein SA, Anderson LD, Kaufman JL, Shah N, Pei H, Patel S, Cortoos A, Bartlett JB, Vermeulen J, Lin TS, Voorhees PM, Richardson PG. PMID: 36111391; PMCID: PMC9825872.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    43. Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma. Leukemia. 2022 12; 36(12):2917-2921. Slade M, Martin TG, Nathwani N, Fiala MA, Rettig MP, Gao F, Deol A, Buadi FK, Kaufman JL, Hofmeister CC, Gregory TK, Berdeja J, Chari A, Rosko A, Vij R. PMID: 36114265; PMCID: PMC10445424.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    44. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discov. 2022 07 06; 3(4):273-284. Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, Kumar SK, Costa LJ, Anderson KC, Morgan GJ. PMID: 35653112; PMCID: PMC9894570.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    45. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2022 08 11; 387(6):495-505. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. PMID: 35661166; PMCID: PMC10587778.
      View in: PubMed   Mentions: 279     Fields:    Translation:HumansCellsCTClinical Trials
    46. A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma. JCO Precis Oncol. 2022 06; 6:e2200147. Restrepo P, Bhalla S, Ghodke-Puranik Y, Aleman A, Leshchenko V, Melnekoff DT, Agte S, Jiang J, Madduri D, Richter J, Richard S, Chari A, Cho HJ, Jagannath S, Walker CJ, Landesman Y, Laganà A, Parekh S. PMID: 35704796; PMCID: PMC10530420.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    47. Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer J. 2022 04 13; 12(4):63. Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Bartlett JB, Vermeulen J, Lin TS, Richardson PG, Voorhees P. PMID: 35418120; PMCID: PMC9007985.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    48. Preferences and Priorities for Relapsed Multiple Myeloma Treatments Among Patients and Caregivers in the United States. Patient Prefer Adherence. 2022; 16:573-585. Auclair D, Mansfield C, Fiala MA, Chari A, Cole CE, Kaufman JL, Orloff GJ, Siegel DS, Zonder JA, Mange B, Yesil J, Dalal M, Mikhael JR. PMID: 35256844; PMCID: PMC8898176.
      View in: PubMed   Mentions: 4  
    49. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb; 9(2):e143-e161. Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, Krishnan A, Hari P, Ludwig H, O'Donnell E, Yee A, Kaufman JL, Cohen AD, Garderet L, Wechalekar AF, Terpos E, Khatry N, Niesvizky R, Yi Q, Joshua DE, Saikia T, Leung N, Engelhardt M, Mothy M, Branagan A, Chari A, Reiman AJ, Lipe B, Richter J, Rajkumar SV, Miguel JS, Anderson KC, Stadtmauer EA, Prabhala RH, McCarthy PL, Munshi NC. PMID: 35114152.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    50. Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer Med. 2022 01; 11(2):358-370. Pan D, Kaufman JL, Htut M, Agrawal M, Mazumder A, Cornell RF, Zonder JA, Fay JW, Modiano MR, Moshier EL, Rush SA, Tunquist BJ, Chari A. PMID: 34921527; PMCID: PMC8729045.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCellsCTClinical Trials
    51. Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications. Sci Adv. 2021 Nov 19; 7(47):eabg9551. Bhalla S, Melnekoff DT, Aleman A, Leshchenko V, Restrepo P, Keats J, Onel K, Sawyer JR, Madduri D, Richter J, Richard S, Chari A, Cho HJ, Dudley JT, Jagannath S, Laganà A, Parekh S. PMID: 34788103; PMCID: PMC8598000.
      View in: PubMed   Mentions: 19     Fields:    
    52. The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 03; 22(3):192-197. Nehlsen AD, Sindhu KK, Moshier E, Richter J, Richard S, Chari A, Sanchez L, Parekh S, Cho HJ, Jagannath S, Dharmarajan K. PMID: 34736880; PMCID: PMC9040190.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    53. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. Expert Rev Hematol. 2021 12; 14(12):1049-1058. Leleu X, Chari A, Richard S, Khurana M, Yusuf A, Usmani SZ. PMID: 34546844.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    54. Treatment Bridging With a 28-Day Metronomic Therapy (Metro-28) for Relapsed Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022 02; 22(2):129-132. Mouhieddine TH, Hieulle J, Moshier E, Richard S, Richter J, Cho HJ, Parekh S, Barlogie B, Chari A, Jagannath S, Madduri D. PMID: 34670732.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    55. Bispecific Antibodies in Multiple Myeloma: Present and Future. Blood Cancer Discov. 2021 Sep; 2(5):423-433. Lancman G, Sastow DL, Cho HJ, Jagannath S, Madduri D, Parekh SS, Richard S, Richter J, Sanchez L, Chari A. PMID: 34661161; PMCID: PMC8510808.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCells
    56. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet. 2021 08 21; 398(10301):665-674. Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. PMID: 34388396.
      View in: PubMed   Mentions: 114     Fields:    Translation:HumansCellsCTClinical Trials
    57. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer. 2021 11 15; 127(22):4198-4212. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Sborov D, Suvannasankha A, Weisel K, Voorhees PM, Womersley L, Baron J, Piontek T, Lewis E, Opalinska J, Gupta I, Cohen AD. PMID: 34314018; PMCID: PMC8597112.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    58. Selinexor for the treatment of patients with previously treated multiple myeloma. Expert Rev Hematol. 2021 08; 14(8):697-706. Mo CC, Jagannath S, Chari A, Nooka AK, Lonial S, Siegel D, Biran N, Gasparetto C, Bahlis NJ, Richardson P. PMID: 33985401.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    59. Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 12; 21(12):e975-e984. Chari A, Florendo E, Mancia IS, Cho H, Madduri D, Parekh S, Richter J, Dhadwal A, Thomas J, Jiang G, Lagana A, Bhalla S, Jagannath S. PMID: 34404623.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    60. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. Am J Hematol. 2021 09 01; 96(9):1120-1130. Richard S, Chari A, Delimpasi S, Simonova M, Spicka I, Pour L, Kriachok I, Dimopoulos MA, Pylypenko H, Auner HW, Leleu X, Usenko G, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Stevens DA, Quach H, Jagannath S, Moreau P, Levy M, Badros A, Anderson LD, Bahlis NJ, Facon T, Mateos MV, Cavo M, Chang H, Landesman Y, Chai Y, Arazy M, Shah J, Shacham S, Kauffman MG, Grosicki S, Richardson PG. PMID: 34062004; PMCID: PMC8457116.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    61. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021 08 09; 39(8):1028-1030. Van Oekelen O, Gleason CR, Agte S, Srivastava K, Beach KF, Aleman A, Kappes K, PVI/Seronet team, Mouhieddine TH, Wang B, Chari A, Cordon-Cardo C, Krammer F, Jagannath S, Simon V, Wajnberg A, Parekh S. PMID: 34242572; PMCID: PMC8238657.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCellsPHPublic Health
    62. Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 11; 21(11):752-765. Berdeja JG, Laubach JP, Richter J, Stricker S, Spencer A, Richardson PG, Chari A. PMID: 34340951.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    63. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 10; 21(10):701-710. Jakubowiak A, Usmani SZ, Krishnan A, Lonial S, Comenzo RL, Wang J, de Boer C, Deraedt W, Weiss BM, Schecter JM, Chari A. PMID: 34274290.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    64. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica. 2021 06 01; 106(6):1725-1732. San-Miguel J, Usmani SZ, Mateos MV, van de Donk NWCJ, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Liu K, Hellemans P, Masterson T, Clemens PL, Luo M, Farnsworth A, Nahi H, Chari A. PMID: 32354874; PMCID: PMC8168515.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    65. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann Hematol. 2021 Sep; 100(9):2325-2337. Davies F, Rifkin R, Costello C, Morgan G, Usmani S, Abonour R, Palumbo A, Romanus D, Hajek R, Terpos E, Cherepanov D, Stull DM, Huang H, Leleu X, Berdeja J, Lee HC, Weisel K, Thompson M, Boccadoro M, Zonder J, Cook G, Puig N, Vela-Ojeda J, Farrelly E, Raju A, Blazer M, Chari A. PMID: 33970288; PMCID: PMC8357697.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    66. Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncol. 2021 Jul; 17(19):2499-2512. Hájek R, Minarík J, Straub J, Pour L, Jungova A, Berdeja JG, Boccadoro M, Brozova L, Spencer A, van Rhee F, Vela-Ojeda J, Thompson MA, Abonour R, Chari A, Cook G, Costello CL, Davies FE, Hungria VT, Lee HC, Leleu X, Puig N, Rifkin RM, Terpos E, Usmani SZ, Weisel KC, Zonder JA, Barinová M, Kuhn M, Šilar J, Cápková L, Galvez K, Lu J, Elliott J, Stull DM, Ren K, Maisnar V. PMID: 33769076.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    67. Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma. Cancer. 2021 06 01; 127(11):1816-1826. Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A. PMID: 33735504; PMCID: PMC8252002.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    68. Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 2021 02 18; 11(2):40. Terpos E, Mikhael J, Hajek R, Chari A, Zweegman S, Lee HC, Mateos MV, Larocca A, Ramasamy K, Kaiser M, Cook G, Weisel KC, Costello CL, Elliott J, Palumbo A, Usmani SZ. PMID: 33602913; PMCID: PMC7891472.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    69. Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 05; 21(5):e470-e476. Lancman G, Lozada K, Athar N, Jacobs S, Doucette J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richard S, Richter J, Chari A. PMID: 33716054.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    70. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Ther Adv Hematol. 2021; 12:2040620720987075. Sanchez L, Richter J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richard S, Tam L, Verina D, Chari A. PMID: 33613930; PMCID: PMC7841854.
      View in: PubMed   Mentions: 4  
    71. Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy. Adv Ther. 2021 02; 38(2):1328-1341. Chari A, Munder M, Weisel K, Jenner M, Bygrave C, Petrucci MT, Boccadoro M, Cavo M, van de Donk NWCJ, Turgut M, Demirkan F, Karadogan I, Libby E, Kleiman R, Kuppens S, Bandekar R, Neff T, Heuck C, Qi M, Clemens PL, Goldschmidt H. PMID: 33474705; PMCID: PMC7889563.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    72. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 12 24; 136(26):3033-3040. Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, García Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H. PMID: 33367546; PMCID: PMC7759145.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCells
    73. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma. Expert Rev Hematol. 2021 01; 14(1):31-45. Richard S, Jagannath S, Cho HJ, Parekh S, Madduri D, Richter J, Chari A. PMID: 33331794.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    74. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. J Clin Oncol. 2021 01 20; 39(3):227-237. Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. PMID: 33326255; PMCID: PMC8078427.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    75. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021 01; 22(1):142-154. Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF, Richardson PG. PMID: 33301738.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    76. Bispecifics, trispecifics, and other novel immune treatments in myeloma. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):264-271. Lancman G, Richter J, Chari A. PMID: 33275733; PMCID: PMC7727546.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    77. Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA. Future Oncol. 2021 Feb; 17(5):503-515. Madduri D, Hagiwara M, Parikh K, Pelletier C, Delea TE, Kee A, Chari A. PMID: 33522834.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    78. Targeting Nuclear Export Proteins in Multiple Myeloma Therapy. Target Oncol. 2020 12; 15(6):697-708. Theodoropoulos N, Lancman G, Chari A. PMID: 33074469; PMCID: PMC7570401.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    79. Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. EJHaem. 2021 Feb; 2(1):48-55. Richardson PG, Jagannath S, Chari A, Vogl DT, Dimopoulos MA, Moreau P, Dingli D, Wei LJ, Richter J, Biran N, Siegel D, Reichmann W, Li L, Tang S, Saint-Martin JR, Joshi A, Kauffman M, Shah J, Shacham S, Lonial S. PMID: 35846096; PMCID: PMC9175889.
      View in: PubMed   Mentions: 5  
    80. Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discov. 2020 11; 1(3):290. Hultcrantz M, Richter J, Rosenbaum CA, Patel D, Smith EL, Korde N, Lu SX, Mailankody S, Shah UA, Lesokhin AM, Hassoun H, Tan C, Maura F, Derkach A, Diamond B, Rossi A, Pearse R, Madduri D, Chari A, Kaminetzky D, Braunstein MJ, Gordillo C, Reshef R, Taur Y, Davies FE, Jagannath S, Niesvizky R, Lentzsch S, Morgan GJ, Landgren O. PMID: 34661147; PMCID: PMC8510790.
      View in: PubMed   Mentions: 14     Fields:    
    81. Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients. J Clin Pharmacol. 2021 05; 61(5):614-627. Luo MM, Usmani SZ, Mateos MV, Nahi H, Chari A, San-Miguel J, Touzeau C, Suzuki K, Kaiser M, Carson R, Heuck C, Qi M, Zhou H, Sun YN, Parasrampuria DA. PMID: 33145788; PMCID: PMC8048619.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    82. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer J. 2020 11 03; 10(11):111. Kaufman JL, Dimopoulos MA, White D, Benboubker L, Cook G, Leiba M, Morton J, Joy Ho P, Kim K, Takezako N, Moreau P, Sutherland HJ, Magen H, Iida S, Kim JS, Miles Prince H, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Trivedi S, Casneuf T, Krevvata M, Ukropec J, Kobos R, Avet-Loiseau H, Usmani SZ, San-Miguel J. PMID: 33149130; PMCID: PMC7643179.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCellsCTClinical Trials
    83. Efficacy and safety of weekly carfilzomib (70 mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leuk Lymphoma. 2021 02; 62(2):358-367. Leleu X, Beksac M, Chou T, Dimopoulos M, Yoon SS, Prince HM, Pour L, Shelekhova T, Chari A, Khurana M, Zhang J, Obreja M, Qi M, Oriol A, Siegel D. PMID: 33112184.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    84. Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH. Am J Hematol. 2021 01; 96(1):E5-E8. Cornell R, Hari P, Tang S, Biran N, Callander N, Chari A, Chhabra S, Fiala MA, Gahvari Z, Gandhi U, Godby K, Gupta R, Jagannath S, Jagosky M, Kang Y, Kansagra A, Kauffman M, Kodali S, Kumar SK, Lakshman A, Liedtke M, Lonial S, Ma X, Malek E, Mansour J, McGehee EF, Neppalli A, Paul B, Richardson P, Scott EC, Shacham S, Shah J, Siegel DS, Umyarova E, Usmani SZ, Varnado W, Vij R, Costa L. PMID: 32974944.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    85. Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma. Ann Hematol. 2021 Dec; 100(12):3057-3060. Mouhieddine TH, Parekh S, Cho HJ, Richter J, DeCastro A, Shah J, Landesman Y, Chari A, Jagannath S, Madduri D. PMID: 33009581.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    86. Immunomodulatory drug- and proteasome inhibitor-backbone regimens in the treatment of relapsed multiple myeloma: an evidence-based review. Expert Rev Hematol. 2020 09; 13(9):943-958. Sanchez L, Barley K, Richter J, Franz J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richard S, Chari A. PMID: 32731770.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    87. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 08 20; 136(8):936-945. Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG. PMID: 32325490; PMCID: PMC7441167.
      View in: PubMed   Mentions: 279     Fields:    Translation:HumansCTClinical Trials
    88. A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma. Leuk Lymphoma. 2020 09; 61(9):2208-2215. Van Oekelen O, Parekh S, Cho HJ, Vishnuvardhan N, Madduri D, Richter J, Ip C, Lau K, Florendo E, Mancia IS, Thomas J, Verina D, Chan E, Zarychta K, La L, Strumolo G, Melnekoff DT, Leshchenko VV, Kim-Schulze S, Couto S, Wang M, Pierceall WE, Thakurta A, Laganà A, Jagannath S, Chari A. PMID: 32812822.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    89. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open-label Phase II study. Br J Haematol. 2021 03; 192(5):869-878. Chari A, Rodriguez-Otero P, McCarthy H, Suzuki K, Hungria V, Sureda Balari A, Perrot A, Hulin C, Magen H, Iida S, Maisnar V, Karlin L, Pour L, Parasrampuria DA, Masterson T, Kosh M, Yang S, Delioukina M, Qi M, Carson R, Touzeau C. PMID: 33216361.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    90. COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discov. 2020 11; 1(3):234-243. Hultcrantz M, Richter J, Rosenbaum CA, Patel D, Smith EL, Korde N, Lu SX, Mailankody S, Shah UA, Lesokhin AM, Hassoun H, Tan C, Maura F, Derkach A, Diamond B, Rossi A, Pearse RN, Madduri D, Chari A, Kaminetzky D, Braunstein MJ, Gordillo C, Reshef R, Taur Y, Davies FE, Jagannath S, Niesvizky R, Lentzsch S, Morgan GJ, Landgren O. PMID: 34651141; PMCID: PMC7668224.
      View in: PubMed   Mentions: 34     Fields:    
    91. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J Hematol Oncol. 2020 07 14; 13(1):94. Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, Richard S, Chari A, Gnjatic S, Merad M, Jagannath S, Parekh S, Madduri D. PMID: 32664919; PMCID: PMC7359431.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCellsPHPublic Health
    92. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 2020 07; 8(2). Shah N, Aiello J, Avigan DE, Berdeja JG, Borrello IM, Chari A, Cohen AD, Ganapathi K, Gray L, Green D, Krishnan A, Lin Y, Manasanch E, Munshi NC, Nooka AK, Rapoport AP, Smith EL, Vij R, Dhodapkar M. PMID: 32661116; PMCID: PMC7359060.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    93. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. medRxiv. 2020 Jun 29. Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, Richard S, Chari A, Gnjatic S, Merad M, Jagannath S, Parekh S, Madduri D. PMID: 32577702; PMCID: PMC7302311.
      View in: PubMed   Mentions:
    94. COVID-19 infections and outcomes in patients with multiple myeloma in New York City: a cohort study from five academic centers. medRxiv. 2020 Jun 11. Hultcrantz M, Richter J, Rosenbaum C, Patel D, Smith E, Korde N, Lu S, Mailankody S, Shah U, Lesokhin A, Hassoun H, Tan C, Maura F, Derkacs A, Diamond B, Rossi A, Pearse RN, Madduri D, Chari A, Kaminetsky D, Braunstein M, Gordillo C, Davies F, Jagannath S, Niesvizky R, Lentzsch S, Morgan G, Landgren O. PMID: 32577667; PMCID: PMC7302217.
      View in: PubMed   Mentions:
    95. Selinexor in relapsed/refractory multiple myeloma. Ther Adv Hematol. 2020; 11:2040620720930629. Richter J, Madduri D, Richard S, Chari A. PMID: 32566115; PMCID: PMC7285937.
      View in: PubMed   Mentions: 15  
    96. Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):e734-e751. Leng S, Moshier E, Tremblay D, Hu L, Biran N, Barman N, Parekh S, Cho H, Madduri D, Richter J, Barlogie B, Jagannath S, Chari A. PMID: 32660906.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    97. Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):632-636.e1. Jatiani SS, Aleman A, Madduri D, Chari A, Cho HJ, Richard S, Richter J, Brody J, Jagannath S, Parekh S. PMID: 32553791; PMCID: PMC7484011.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    98. Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma. Hematol Oncol. 2020 Aug; 38(3):353-362. Chari A, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Lunning M, Usmani SZ, Anderson LD, Chhabra S, Girnius S, Shustik C, Stuart R, Lee Y, Salman Z, Liu E, Valent J. PMID: 32053229; PMCID: PMC7496325.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    99. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev Hematol. 2020 04; 13(4):421-433. Chari A, Richardson PG, Romanus D, Dimopoulos MA, Sonneveld P, Terpos E, Hajek R, Raju A, Palumbo A, Cain LE, Blazer M, Huang H, Farrelly E, Ailawadhi S. PMID: 32148109.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    100. Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor. Clin Lymphoma Myeloma Leuk. 2020 06; 20(6):351-357. Mikhael J, Noonan KR, Faiman B, Gleason C, Nooka AK, Costa LJ, Jagannath S, Richardson PG, Siegel D, Chari A, Lentzch S. PMID: 32245742.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    101. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 05; 189(4):e126-e130. Chari A, Vogl DT, Jagannath S, Jasielec J, Unger TJ, DeCastro A, Shah J, Kauffman M, Shacham S, Jakubowiak A. PMID: 32124443.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    102. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 09; 34(9):2430-2440. Gavriatopoulou M, Chari A, Chen C, Bahlis N, Vogl DT, Jakubowiak A, Dingli D, Cornell RF, Hofmeister CC, Siegel D, Berdeja JG, Reece D, White D, Lentzsch S, Gasparetto C, Huff CA, Jagannath S, Baz R, Nooka AK, Richter J, Abonour R, Parker TL, Yee AJ, Moreau P, Lonial S, Tuchman S, Weisel KC, Mohty M, Choquet S, Unger TJ, Li K, Chai Y, Li L, Shah J, Shacham S, Kauffman MG, Dimopoulos MA. PMID: 32094461; PMCID: PMC7449872.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    103. MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1. Oncotarget. 2020 Feb 18; 11(7):727-739. Mei AH, Tung K, Han J, Perumal D, Laganà A, Keats J, Auclair D, Chari A, Jagannath S, Parekh S, Cho HJ. PMID: 32133047; PMCID: PMC7041939.
      View in: PubMed   Mentions: 12     Fields:    
    104. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020 04; 34(4):985-1005. Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. PMID: 32055000; PMCID: PMC7214244.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansCells
    105. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia. 2020 07; 34(7):1840-1852. Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, Sandhu I, Jenner MW, Williams C, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Kuppens S, Bandekar R, Clemens PL, Neff T, Heuck C, Qi M, Hofmeister CC. PMID: 32024950; PMCID: PMC7326703.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    106. Selinexor for the treatment of multiple myeloma. Expert Opin Pharmacother. 2020 Mar; 21(4):399-408. Podar K, Shah J, Chari A, Richardson PG, Jagannath S. PMID: 31957504.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    107. Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2. Am J Hematol. 2020 02; 95(2):E51-E54. Barley K, Sanchez L, Cho HJ, Parekh S, Madduri D, Richter J, Isola L, Goldstein T, Dhadwal A, Zarychta K, Sanchez GM, Catamero D, Verina D, Florendo E, Yum MH, La L, Gullie J, Chan E, Jagannath S, Chari A. PMID: 31814152.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    108. Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clin Cancer Res. 2020 01 15; 26(2):450-464. Perumal D, Imai N, Laganà A, Finnigan J, Melnekoff D, Leshchenko VV, Solovyov A, Madduri D, Chari A, Cho HJ, Dudley JT, Brody JD, Jagannath S, Greenbaum B, Gnjatic S, Bhardwaj N, Parekh S. PMID: 31857430; PMCID: PMC6980765.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    109. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 02; 21(2):207-221. Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kortüm KM, Rodríguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. PMID: 31859245.
      View in: PubMed   Mentions: 329     Fields:    Translation:HumansCTClinical Trials
    110. Selinexor for Refractory Multiple Myeloma. Reply. N Engl J Med. 2019 11 14; 381(20):1977-1978. Chari A, Vogl DT, Jagannath S. PMID: 31722163.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    111. Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark Randomized Clinical Trials of Relapsed/Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 01; 20(1):8-17.e16. Chari A, Romanus D, Palumbo A, Blazer M, Farrelly E, Raju A, Huang H, Richardson P. PMID: 31722839.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    112. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 08 22; 381(8):727-738. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. PMID: 31433920.
      View in: PubMed   Mentions: 260     Fields:    Translation:HumansCTClinical Trials
    113. Patient-Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Oncologist. 2019 11; 24(11):1479-1487. Chari A, Romanus D, DasMahapatra P, Hoole M, Lowe M, Curran C, Campbell S, Bell JA. PMID: 31371520; PMCID: PMC6853123.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    114. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019 08 22; 134(8):668-677. Usmani SZ, Nahi H, Mateos MV, van de Donk NWCJ, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benboubker L, Hellemans P, Masterson T, Clemens PL, Luo M, Liu K, San-Miguel J. PMID: 31270103; PMCID: PMC6754719.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCTClinical Trials
    115. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting. Clin Lymphoma Myeloma Leuk. 2019 10; 19(10):645-655. Chari A, Parikh K, Ni Q, Abouzaid S. PMID: 31377207.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    116. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019 08; 186(4):549-560. Jakubowiak AJ, Jasielec JK, Rosenbaum CA, Cole CE, Chari A, Mikhael J, Nam J, McIver A, Severson E, Stephens LA, Tinari K, Rosebeck S, Zimmerman TM, Hycner T, Turowski A, Karrison T, Zonder JA. PMID: 31124580; PMCID: PMC6772147.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    117. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019 08 01; 134(5):421-431. Chari A, Martinez-Lopez J, Mateos MV, Bladé J, Benboubker L, Oriol A, Arnulf B, Rodriguez-Otero P, Pineiro L, Jakubowiak A, de Boer C, Wang J, Clemens PL, Ukropec J, Schecter J, Lonial S, Moreau P. PMID: 31113777; PMCID: PMC6676132.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    118. Management and outcomes of proteasome inhibitor associated chalazia and blepharitis: a case series. BMC Ophthalmol. 2019 May 14; 19(1):110. Sklar BA, Gervasio KA, Leng S, Ghosh A, Chari A, Wu AY. PMID: 31088416; PMCID: PMC6518763.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    119. Daratumumab-induced transient myopic shift. Am J Ophthalmol Case Rep. 2019 Mar; 13:116-118. Mavrommatis MA, Jung H, Chari A, Barlogie B, Chelnis JG. PMID: 30619976; PMCID: PMC6312830.
      View in: PubMed   Mentions: 2  
    120. Blood Transfusion Management for Patients Treated With Anti-CD38 Monoclonal Antibodies. Front Immunol. 2018; 9:2616. Lancman G, Arinsburg S, Jhang J, Cho HJ, Jagannath S, Madduri D, Parekh S, Richter J, Chari A. PMID: 30498492; PMCID: PMC6249335.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    121. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer. 2018 11 15; 124(22):4342-4349. Chari A, Lonial S, Mark TM, Krishnan AY, Stockerl-Goldstein KE, Usmani SZ, Londhe A, Etheredge D, Fleming S, Liu B, Ukropec J, Lin TS, Jagannath S, Nooka AK. PMID: 30395359; PMCID: PMC6587745.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    122. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 12; 103(12):2088-2096. Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ. PMID: 30237262; PMCID: PMC6269302.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCTClinical Trials
    123. Imipridone ONC201: combination therapy in hematologic malignancies. Cell Cycle. 2018; 17(16):1947-1948. Chari A, Barlogie B. PMID: 29929441; PMCID: PMC6224273.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    124. Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach. JCO Precis Oncol. 2018; 2018. Laganà A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D, Sanchez L, Niglio S, Perumal D, Kidd BA, Miotto R, Shaknovich R, Chari A, Cho HJ, Barlogie B, Jagannath S, Dudley JT, Parekh S. PMID: 30706044; PMCID: PMC6350920.
      View in: PubMed   Mentions: 17     Fields:    
    125. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood Adv. 2018 07 10; 2(13):1633-1644. Chari A, Stewart AK, Russell SD, Moreau P, Herrmann J, Banchs J, Hajek R, Groarke J, Lyon AR, Batty GN, Ro S, Huang M, Iskander KS, Lenihan D. PMID: 29991494; PMCID: PMC6039655.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    126. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018 06 26; 2(12):1470-1479. Wu V, Moshier E, Leng S, Barlogie B, Cho HJ, Jagannath S, Madduri D, Mazumdar M, Parekh S, Chari A. PMID: 29945937; PMCID: PMC6020804.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    127. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. Br J Haematol. 2018 07; 182(2):231-244. Richardson PG, Hofmeister CC, Rosenbaum CA, Htut M, Vesole DH, Berdeja JG, Liedtke M, Chari A, Smith SD, Lebovic D, Raje N, Byrne C, Liao E, Gupta N, Bacco AD, Estevam J, Berg D, Baz R. PMID: 29938772; PMCID: PMC6055619.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    128. Treatment patterns and medication adherence among patients diagnosed with multiple myeloma and treated with panobinostat. Future Oncol. 2018 Sep; 14(21):2149-2160. Chari A, Bhor M, Eldjerou L, Gilligan AM, Urniasz A, Globe D, Stetsovsky D, Varker H, Davis B, Bonafede M, Talcott J. PMID: 29846095.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    129. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2018 11; 59(11):2588-2594. Chari A, Larson S, Holkova B, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Valent J, Lunning M, Usmani SZ, Anderson LD, Chang L, Lee Y, Pak Y, Salman Z, Graef T, Bilotti E, Chhabra S. PMID: 29616843.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    130. Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018 05; 18(5):335-345. Gandhi UH, Senapedis W, Baloglu E, Unger TJ, Chari A, Vogl D, Cornell RF. PMID: 29610030.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    131. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma. J Clin Oncol. 2018 03 20; 36(9):859-866. Vogl DT, Dingli D, Cornell RF, Huff CA, Jagannath S, Bhutani D, Zonder J, Baz R, Nooka A, Richter J, Cole C, Vij R, Jakubowiak A, Abonour R, Schiller G, Parker TL, Costa LJ, Kaminetzky D, Hoffman JE, Yee AJ, Chari A, Siegel D, Fonseca R, Van Wier S, Ahmann G, Lopez I, Kauffman M, Shacham S, Saint-Martin JR, Picklesimer CD, Choe-Juliak C, Stewart AK. PMID: 29381435; PMCID: PMC6905485.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    132. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United States. Clin Lymphoma Myeloma Leuk. 2018 02; 18(2):152-160. Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, Raju A, Farrelly E, Noga SJ, Blazer M, Chari A. PMID: 29395837.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    133. The effect of novel therapies in high-molecular-risk multiple myeloma. Clin Adv Hematol Oncol. 2017 Nov; 15(11):870-879. Lancman G, Tremblay D, Barley K, Barlogie B, Cho HJ, Jagannath S, Madduri D, Moshier E, Parekh S, Chari A. PMID: 29200420; PMCID: PMC5993678.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    134. Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2018 01; 18(1):44-51. Chari A, Arinsburg S, Jagannath S, Satta T, Treadwell I, Catamero D, Morgan G, Feng H, Uhlar C, Khan I, Doshi P, Usmani S. PMID: 29054515.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    135. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017 Aug 22; 1(19):1575-1583. Chari A, Cho HJ, Dhadwal A, Morgan G, La L, Zarychta K, Catamero D, Florendo E, Stevens N, Verina D, Chan E, Leshchenko V, Laganà A, Perumal D, Mei AH, Tung K, Fukui J, Jagannath S, Parekh S. PMID: 29296798; PMCID: PMC5728465.
      View in: PubMed   Mentions: 17     Fields:    
    136. Characteristics of Vitamin B12 Deficiency in Patients With Plasma Cell Disorders. Clin Lymphoma Myeloma Leuk. 2017 Dec; 17(12):e65-e69. Braschi C, Doucette J, Chari A. PMID: 28757000.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    137. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):555-562. van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R. PMID: 28735890.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    138. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 08 24; 130(8):974-981. Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. PMID: 28637662; PMCID: PMC5570682.
      View in: PubMed   Mentions: 180     Fields:    Translation:HumansCTClinical Trials
    139. Management of Patients With Hepatitis C Virus, Monoclonal Gammopathy of Undetermined Significance, and Multiple Myeloma. J Investig Med High Impact Case Rep. 2017 Apr-Jun; 5(2):2324709617696854. Hannaford A, Del Bello D, Leng S, Chari A, Perumalswami P, Dieterich D, Branch A. PMID: 28748190; PMCID: PMC5510768.
      View in: PubMed   Mentions:    Fields:    
    140. Treating Multiple Myeloma Patients With Oral Therapies. Clin Lymphoma Myeloma Leuk. 2017 05; 17(5):243-251. Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A. PMID: 28347676.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    141. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. PMID: 28018601; PMCID: PMC5168808.
      View in: PubMed   Mentions: 14     Fields:    
    142. Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study. BMC Cancer. 2016 11 22; 16(1):912. Chari A, Mezzi K, Zhu S, Werther W, Felici D, Lyon AR. PMID: 27876016; PMCID: PMC5120425.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    143. Incidence and Risk of Cardiac Events in Patients With Previously Treated Multiple Myeloma Versus Matched Patients Without Multiple Myeloma: An Observational, Retrospective, Cohort Study. Clin Lymphoma Myeloma Leuk. 2017 02; 17(2):89-96.e3. Kistler KD, Kalman J, Sahni G, Murphy B, Werther W, Rajangam K, Chari A. PMID: 28025038.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    144. A phase II trial of TBL-12 sea cucumber extract in patients with untreated asymptomatic myeloma. Br J Haematol. 2018 01; 180(2):296-298. Chari A, Mazumder A, Lau K, Catamero D, Galitzeck Z, Jagannath S. PMID: 27714761.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    145. A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent/refractory multiple myeloma. Cancer. 2016 Nov 15; 122(21):3327-3335. Chari A, Htut M, Zonder JA, Fay JW, Jakubowiak AJ, Levy JB, Lau K, Burt SM, Tunquist BJ, Hilder BW, Rush SA, Walker DH, Ptaszynski M, Kaufman JL. PMID: 27433944; PMCID: PMC6857452.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    146. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016 07 07; 128(1):37-44. Usmani SZ, Weiss BM, Plesner T, Bahlis NJ, Belch A, Lonial S, Lokhorst HM, Voorhees PM, Richardson PG, Chari A, Sasser AK, Axel A, Feng H, Uhlar CM, Wang J, Khan I, Ahmadi T, Nahi H. PMID: 27216216; PMCID: PMC4937359.
      View in: PubMed   Mentions: 176     Fields:    Translation:HumansCTClinical Trials
    147. A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis. Br J Haematol. 2016 Sep; 174(5):748-59. Gupta N, Hanley MJ, Harvey RD, Badros A, Lipe B, Kukreti V, Berdeja J, Yang H, Hui AM, Qian M, Zhang X, Venkatakrishnan K, Chari A. PMID: 27196567; PMCID: PMC5084759.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    148. Validation and Utility of the Free Light Chain Assay in Pleural Effusions of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):e113-7. Marron TU, Hanna MG, Ramanathan L, Chari A. PMID: 27349767.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    149. Diagnostic Advances in Multiple Myeloma. Curr Hematol Malig Rep. 2016 Apr; 11(2):111-7. Barley K, Chari A. PMID: 26922745.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    150. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leuk Lymphoma. 2016 11; 57(11):2510-5. Barley K, He W, Agarwal S, Jagannath S, Chari A. PMID: 26943456.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    151. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 2016 05 26; 127(21):2561-8. Baz RC, Martin TG, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. PMID: 26932802.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    152. Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Res. 2016 Mar 01; 76(5):1225-36. Perumal D, Kuo PY, Leshchenko VV, Jiang Z, Divakar SK, Cho HJ, Chari A, Brody J, Reddy MV, Zhang W, Reddy EP, Jagannath S, Parekh S. PMID: 26873845; PMCID: PMC5968814.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    153. The outcomes of newly diagnosed elderly multiple myeloma patients treated at a single U.S. institution. Cancer Med. 2016 Mar; 5(3):500-5. Bonomo L, Lue J, Jagannath S, Chari A. PMID: 26799254; PMCID: PMC4799960.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    154. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016 Apr 09; 387(10027):1551-1560. Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Bladé J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM. PMID: 26778538.
      View in: PubMed   Mentions: 366     Fields:    Translation:HumansCTClinical Trials
    155. Characterization of central nervous system multiple myeloma in the era of novel therapies. Leuk Lymphoma. 2016 07; 57(7):1709-13. Majd N, Wei X, Demopoulos A, Hormigo A, Chari A. PMID: 26727654.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    156. CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma. Biol Blood Marrow Transplant. 2016 Feb; 22(2):258-267. Smith E, Devlin SM, Kosuri S, Orlando E, Landau H, Lesokhin AM, Chung DJ, Hassoun H, Lendvai N, Landgren O, Giralt S, Chari A, Jagannath S, Koehne G. PMID: 26325439; PMCID: PMC4975432.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    157. The characterization of adrenal insufficiency and identification of its risk factors in patients with plasma cell dyscrasias. Am J Hematol. 2015 Oct; 90(10):E202-3. Tremblay D, Choudhury N, Ravikumar A, Levine AC, Chari A. PMID: 26178513.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    158. Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2015 Sep; 15(9):541-5. Barley K, Tindle S, Bagiella E, Jagannath S, Chari A. PMID: 26119495.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    159. Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment. BMC Cancer. 2015 May 30; 15:444. Adomako A, Calvo V, Biran N, Osman K, Chari A, Paton JC, Paton AW, Moore K, Schewe DM, Aguirre-Ghiso JA. PMID: 26025442; PMCID: PMC4448210.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    160. Outcome of patients with multiple myeloma and hypotension during high-dose chemotherapy. Am J Hematol. 2015 Jun; 90(6):E125-7. Biran N, Sehgal P, Sahni G, Doucette J, Chari A. PMID: 25732327.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    161. Diagnostic utility of measuring free light chains in the cerebrospinal fluid of patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):e127-31. Marron TU, Ramanathan L, Chari A. PMID: 25846395.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    162. Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring. BMC Cancer. 2014 Dec 04; 14:915. Chari A, Hajje D. PMID: 25471129; PMCID: PMC4289164.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    163. What we mean when we talk about MRD in myeloma. A review of current methods. Part 1 of a two-part series. Curr Hematol Malig Rep. 2014 Dec; 9(4):379-88. Ely S, Biran N, Chari A. PMID: 25277219.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    164. Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal residual disease negativity using highly sensitive techniques. Curr Hematol Malig Rep. 2014 Dec; 9(4):368-78. Biran N, Ely S, Chari A. PMID: 25224462.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    165. Imaging of extraosseous intracranial and intraspinal multiple myeloma, including central nervous system involvement. Clin Imaging. 2015 Mar-Apr; 39(2):213-9. Shpilberg KA, Esses SJ, Fowkes ME, Chari A, Sacher M, Naidich TP. PMID: 25547625.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    166. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol. 2014 Dec; 83(12):2203-2223. Mesguich C, Fardanesh R, Tanenbaum L, Chari A, Jagannath S, Kostakoglu L. PMID: 25308249.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    167. Patients with newly diagnosed multiple myeloma and chromosome 1 amplification have poor outcomes despite the use of novel triplet regimens. Am J Hematol. 2014 Jun; 89(6):616-20. Biran N, Malhotra J, Bagiella E, Cho HJ, Jagannath S, Chari A. PMID: 24616227.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    168. A case of IgD myeloma representing a missed biclonal paraproteinemia or isotype switch in a patient previously diagnosed with IgA-lambda myeloma. Clin Chim Acta. 2013 Oct 21; 425:233-5. Chepovetsky J, Chari A, Jagannath S, Ramanthan L. PMID: 23954772.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    169. Risk stratification in multiple myeloma, part 1: characterization of high-risk disease. Clin Adv Hematol Oncol. 2013 Aug; 11(8):489-503. Biran N, Jagannath S, Chari A. PMID: 24518420.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    170. Complete remission achieved with single agent CNTO 328, an anti-IL-6 monoclonal antibody, in relapsed and refractory myeloma. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):333-7. Chari A, Pri-Chen H, Jagannath S. PMID: 23313067.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    171. Risk stratification in multiple myeloma, part 2: the significance of genetic risk factors in the era of currently available therapies. Clin Adv Hematol Oncol. 2013; 11(9):578-83. Biran N, Jagannath S, Chari A. PMID: 24518521.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    172. A case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):175-9. Ragupathi L, Najfeld V, Chari A, Petersen B, Jagannath S, Mascarenhas J. PMID: 23168212.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    173. Misdiagnosis of non-hodgkin lymphoma as multiple myeloma. J Clin Oncol. 2012 Dec 10; 30(35):e364-7. Barley K, Harris JA, Diefenbach C, Jagannath S, Chari A. PMID: 23109698.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    174. Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis. Clin Lymphoma Myeloma Leuk. 2013 Feb; 13(1):55-61. Chari A, Barley K, Jagannath S, Osman K. PMID: 23098888.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    175. Erectile dysfunction associated with bortezomib treatment in a patient with multiple myeloma and amyloidosis. Clin Lymphoma Myeloma Leuk. 2013 Jun; 13(3):331-2. Pri-Chen H, Chari A. PMID: 23084404.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    176. Risk stratification of plasma cell neoplasm: insights from plasma cell-specific cytoplasmic immunoglobulin fluorescence in situ hybridization (cIg FISH) vs. conventional FISH. Clin Lymphoma Myeloma Leuk. 2012 Oct; 12(5):366-74. Dong H, Yang HS, Jagannath S, Stephenson CF, Brenholz P, Mazumder A, Chari A. PMID: 22658896.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    177. Proteasome inhibition and its therapeutic potential in multiple myeloma. Biologics. 2010 Sep 28; 4:273-87. Chari A, Mazumder A, Jagannath S. PMID: 21116326; PMCID: PMC2990320.
      View in: PubMed   Mentions: 10  
    Ajai's Networks
    Concepts (315)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (16)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-8-gc1ed69da on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.